Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.
Stanford is currently accepting patients for this trial.
Heike E Daldrup-Link
- Drug: Feraheme
- Procedure: Magnetic Resonance Imaging (MRI) scan
- Age 10 to 21 years
- Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis
- Informed consent with assent as appropriate.
- Contraindication to MRI
- Presence of metal implants
- Need for sedation or anesthesia
- Hemosiderosis or hemochromatosis
- History of allergic reactions to similar compounds will be obtained and patients with
positive history of allergic reactions will be excluded from the study
- Females who are pregnancy or nursing
Ages Eligible for Study
10 Years - 21 Years
Genders Eligible for Study